Ethoxzolamide
FDA-approved product (tablet, oral), marketed as Cardrase, Ethamide.
- Registered studies
- 0
- Lab records
- 2
- Pathogens at ≥40%
- 1 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLNo approved indication recorded
ChEMBL records no approved indication for Ethoxzolamide. Its therapeutic class is shown instead.
- Anti-infective classification
- Neither a WHO ATC code nor an FDA pharmacologic class was found for it, so whether it is already an antimicrobial is not established. It needs review and is not counted as a repurposing candidate.
Repurposing investigation
Ethoxzolamide reaches ≥40% AI-predicted activity against M. tuberculosis, but no WHO ATC code or FDA pharmacologic class says whether it is already an antimicrobial. It needs review, so it is not counted among the repurposing candidates.
AI-predicted activity
AI prediction · nothing measured- MRSA37.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- E. coli34.7% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- K. pneumoniae14.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis82.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
No evidence found
The registry was searched and no registered study names this medicine.
Experimental
- M. tuberculosis: measured active in 2 of 2 lab records
Show the 2 laboratory records, with sources
Loading records…
“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.
Docking
Computational · nothing measuredDihydrofolate reductase ↗ (MRSA)
Not yet docked: queued in the docking rundetails
AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Ethoxzolamide with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- Nirogacestat HydrobromideExisting use: Gastrointestinal desmoid tumor47.9% AI-predicted activityagainst E. coli1 registered study
- Naratriptan HydrochlorideExisting use: Migraine disorder47.7% AI-predicted activityagainst E. coli4 registered studies
- Tepotinib HydrochlorideExisting use: Cancer, Neoplasm, Non-small cell lung carcinoma47.7% AI-predicted activityagainst E. coli6 registered studies
- Cobimetinib FumarateExisting use: Cancer, Melanoma, Metastatic melanoma and 1 more47.6% AI-predicted activityagainst E. coliNo documented evidence found
- RevefenacinExisting use: Airway obstruction, Chronic obstructive pulmonary disease47.5% AI-predicted activityagainst E. coli20 registered studies
- SotorasibExisting use: Neoplasm, Non-small cell lung carcinoma47.3% AI-predicted activityagainst E. coli50+ registered studies
- Vincristine SulfateExisting use: Neoplasm47.2% AI-predicted activityagainst E. coli50+ registered studies
- BrexpiprazoleExisting use: Major depressive disorder, Psychosis, Schizoaffective disorder and 1 more47.2% AI-predicted activityagainst E. coli50+ registered studies
- Octreotide AcetateExisting use: Acromegaly, Carcinoid tumor, Metastasis and 1 more47.0% AI-predicted activityagainst E. coli50+ registered studies
- DeserpidineExisting use: Hypertension47.0% AI-predicted activityagainst E. coliNo documented evidence found
- Ioflupane I-123Existing use: Abnormality of movement, Alzheimer disease, Computed tomography and 7 more47.0% AI-predicted activityagainst E. coli36 registered studies
- Montelukast SodiumExisting use: Airway obstruction, Allergic rhinitis, Asthma and 2 more46.9% AI-predicted activityagainst E. coli50+ registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
No evidence found: the registry was searched and no registered study names this medicine.